Scotia Capital’s AbbVie ABBV Stock Holding History

Scotia Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,000	Closed	-$1.09M	–	797
2015 Q3	$1.09M	Buy	+20,000	New	+$1.3M	0.02%	374

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Scotia Capital's ABBV Position: Q2 2026 in Review

Scotia Capital increased its AbbVie (ABBV) stake by 2.1% in Q2 2026, buying an estimated $830K and bringing the position to 187,501 shares worth $47.2M. The position accounts for 0.18% of the portfolio, ranked #82.

Scotia Capital first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Scotia Capital held 187,501 shares of AbbVie worth $47.2M as of Q2 2026.
Scotia Capital bought 3,858 AbbVie shares in Q2 2026, an estimated $830K.
AbbVie made up 0.18% of Scotia Capital's portfolio in Q2 2026, its #82 holding.
Scotia Capital first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.